Medication info
Daewoong Rosuvastatin Tablets 10 mg (Rosuvastatin Calcium (Unmicronized))

Daewoong Rosuvastatin Tablets 10 mg (Rosuvastatin Calcium (Unmicronized))

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium Micronized›10.4mg / 1 tablet
Manufacturer / importer
Daewoong Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201000977 · Approved 2010.01.28 · Insurance code 641604600

Summary

Main use
Treatment of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased up to a maximum of 20 mg daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.
Child dose
2. Pediatric patients with heterozygous familial hypercholesterolemia (aged 10 to 17 years) The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or more. Safety and efficacy have not been established in children younger than 10 years.

Ingredients

Manufacturer
Daewoong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • dyslipidemia
  • dysbetalipoproteinemia
  • cardiovascular disease risk factors
  • stroke risk
  • myocardial infarction risk
  • risk of vascular intervention
View approved original text

This medication is used for various conditions related to hypercholesterolemia. It is helpful in patients with primary hypercholesterolemia or mixed dyslipidemia that is not controlled by diet and exercise. In particular, it acts as an adjunctive therapy for patients with familial hypercholesterolemia, lowering total cholesterol and LDL-cholesterol levels to delay the progression of atherosclerosis. It is also used in pediatric patients aged 10 to 17 years when dietary therapy is insufficient. Additionally, it is effective as an adjunct to diet for patients with primary dysbetalipoproteinemia. For high-risk cardiovascular disease patients with elevated high-sensitivity C-reactive protein, it helps reduce the risk of stroke, myocardial infarction, and vascular interventions. Overall, this medication improves hypercholesterolemia and cardiovascular risk.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased up to a maximum of 20 mg daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.

Child dose

2. Pediatric patients with heterozygous familial hypercholesterolemia (aged 10 to 17 years) The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or more. Safety and efficacy have not been established in children younger than 10 years.

Precautions

This medication should not be used in individuals allergic to certain ingredients. Patients with active liver disease or markedly elevated liver enzyme levels should not take this medication. Patients with muscle diseases or muscle-related problems should also avoid this drug. It is not indicated for patients taking cyclosporine or those with severe renal impairment, as well as pregnant or breastfeeding women. Women of childbearing potential should confirm a low likelihood of pregnancy before taking this medication and be fully aware of the risks to the fetus. High-dose use of this drug should be avoided in patients at risk of myopathy or rhabdomyolysis, including those with renal impairment, hypothyroidism, a history of genetic muscle disorders, or alcohol use disorder. This medication contains lactose and should not be given to patients with lactose intolerance or certain genetic metabolic disorders. Patients with a history of liver disease or excessive alcohol consumption should have regular liver function tests, and those with hypothyroidism or nephrotic syndrome should treat the underlying causes first. If symptoms such as myalgia, muscle weakness, or cramps occur, immediate consultation with a physician is required, and blood tests should be conducted if necessary to check for muscle damage. In cases of acute severe conditions or serious illnesses, discontinuation of this medication may be necessary. This medication can rarely induce severe muscle weakness or ocular myasthenia, so it should be stopped if relevant symptoms arise. Caution is needed when co-administered with certain drugs that may increase the risk of muscle damage. Regular kidney function tests are recommended during high-dose administration. Asian patients may have increased drug exposure, necessitating dosage adjustments. This medication is also used in pediatric patients, but any effects on growth and development are limited and require caution. Some patients may experience side effects such as headaches, dizziness, dyspepsia, myalgia, and if symptoms are severe, consultation with a physician is advised. Periodic testing is recommended due to possible liver function abnormalities or changes in kidney function. If there are severe skin reactions or allergic symptoms, immediate discontinuation of the medication and consultation with healthcare providers are necessary. Pregnant or breastfeeding women should not take this medication and should use appropriate contraception if planning for pregnancy. In case of overdose, there is no specific antidote, and treatment is based on symptoms with monitoring of liver and muscle function. This medication does not significantly affect the ability to drive or operate machinery, but caution is warranted as dizziness may occur. There may be drug interactions; therefore, patients should inform healthcare providers of any other medications they are taking.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, shortness of breath, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), morbilliform drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, fatigue, numbness, paresthesia, discomfort in the chest, loss of appetite, abdominal distension, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.